|
Relationship between peripheral-blood immuno-inflammatory markers, radiotherapy efficacy, and 1-year overall survival rate among patients with stage III non-small cell lung cancer
|
T. Li Li   , B. Han , Q. Dong , D. Ji |
| Department of Pulmonary and Critical Care Medicine, General Hospital of Benxi Iron, Liaoning Province, China , ty13841402@hotmail.com |
|
|
Abstract: (43 Views) |
Background: Locally advanced non-small cell lung cancer (NSCLC) is often associated with unfavorable clinical outcomes. This study aims to examine the association between peripheral immuno-inflammatory biomarkers, the effectiveness of radiotherapy, and 1-year survival rates in stage III NSCLC. Materials and Methods: This study reviewed 180 stage III NSCLC patients treated with radical radiotherapy from 2020 to 2024. Pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune inflammation index (SII), and lymphocyte-to-monocyte ratio (LMR) levels were measured and compared with healthy controls. Biomarker differences were analyzed across clinical subgroups and between radiotherapy response groups. Using median values as cutoffs, one-year survival data were assessed, with Cox regression determining prognostic factors. Results: Patients with NSCLC had significantly higher NLR, PLR, and SII and lower LMR than the control group (P<0.05). The good-response group had lower NLR, PLR, and SII and higher LMR (P<0.05). Higher NLR, PLR, and SII were associated with worse 1-year survival, while higher LMR predicted better outcomes (P<0.05). Cox analysis confirmed that all four markers were independent prognostic factors (P<0.05). Conclusion: The peripheral blood markers NLR, PLR, SII, and LMR are closely associated with radiotherapy efficacy and 1-year survival in stage III NSCLC. |
|
| Keywords: Carcinoma, non-small-cell lung, inflammatory markers, radiotherapy, survival rate, stage III neoplasms. |
|
|
Full-Text [PDF 959 kb]
(5 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
